Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein

Hugle, 2019, Identification of Smac mimetics as novel substrates for P-glycoprotein, Cancer Lett., 440–441, 126, 10.1016/j.canlet.2018.10.001 Salaroglio, 2018, New tetrahydroisoquinoline derivatives overcome Pgp activity in brain-blood barrier and glioblastoma multiforme in vitro, Molecules, 23, 10.3390/molecules23061401 Chegaev, 2017, Light-regulated NO release as a novel strategy to overcome doxorubicin multidrug resistance, ACS Med. Chem. Lett., 8, 361, 10.1021/acsmedchemlett.7b00016 Franco, 2018, Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer, Breast Cancer.: Targets Ther. (Dove Med Press), 10, 131 October 〈https://clinicaltrials.gov/〉 (accessed on 20 2021). Thomas, 2003, Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein, Cancer Control, 10, 159, 10.1177/107327480301000207 Lai, 2020, Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics, Front. Oncol., 10, 10.3389/fonc.2020.561936 Dallavalle, 2020, Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors, Drug Resist. Updat., 50, 10.1016/j.drup.2020.100682 Wink, 2012, Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents, Front. Microbiol., 3, 1, 10.3389/fmicb.2012.00130 Zhang, 2003, Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport, J. Pharmacol. Exp. Ther., 304, 1258, 10.1124/jpet.102.044412 Nabekura, 2005, Effects of dietary chemopreventive phytochemicals on P-glycoprotein function, Biochem. Biophys. Res. Commun., 327, 866, 10.1016/j.bbrc.2004.12.081 Yu, 2016, Advances in plant-based inhibitors of P-glycoprotein, J. Enzym. Inhib. Med. Chem., 31, 867, 10.3109/14756366.2016.1149476 Critchfield, 1994, Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism, Biochem Pharm., 48, 1437, 10.1016/0006-2952(94)90568-1 Pelter, 1981, 8-Substituted flavonoids and 3′-substituted 7-oxygenated chalcones from Tephrosia purpurea, J. Chem. Soc. Perkin Trans., 1, 2491, 10.1039/P19810002491 Hegazy, 2009, Rare prenylated flavonoids from Tephrosia purpurea, Phytochemistry, 70, 1474, 10.1016/j.phytochem.2009.08.001 Mohamed, 2008, Biotransformation of glabratephrin, a rare type of isoprenylated flavonoids, by Aspergillus niger, Z. fur Naturforsch. - Sect. C. J. Biosci., 63, 561, 10.1515/znc-2008-7-816 Ammar, 2013, Antifungal activity of prenylated flavonoids isolated from Tephrosia apollinea L. against four phytopathogenic fungi, Crop Prot., 49, 21, 10.1016/j.cropro.2013.02.012 Vleggaar, 1978, Flavonoids from Tephrosia—XI1: The structure of glabratephrin, Tetrahedron, 34, 1405, 10.1016/0040-4020(78)88338-0 Chen, 2018, Glabridin induces apoptosis and cell cycle arrest in oral cancer cells through the JNK1/2 signaling pathway, Environ. Toxicol., 33, 679, 10.1002/tox.22555 Qian, 2019, Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents, Eur. J. Pharm., 852, 231, 10.1016/j.ejphar.2019.04.002 Molnar, 2006, Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids, Curr. Pharm. Des., 12, 287, 10.2174/138161206775201893 Székely, 2017, New therapeutic strategies for triple-negative breast cancer, Oncol. (Williston Park), 31, 130 Riganti, 2015, The role of C/EBP-β LIP in multidrug resistance, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv046 Kopecka, 2014, Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition, Nanomedicine, 10, 77, 10.1016/j.nano.2013.06.013 Esser, 2017, Structures of the multidrug transporter P-glycoprotein reveal asymmetric ATP binding and the mechanism of polyspecificity, J. Biol. Chem.., 292, 446, 10.1074/jbc.M116.755884 Aller, 2009, Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding, Science, 323, 1718, 10.1126/science.1168750 Riganti, 2011, Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells, Mol. Pharm., 8, 683, 10.1021/mp2001389 Lee, 2003, Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol. Res., 14, 49 Gottesman, 2002, Multidrug resistance in cancer: Role of ATP–dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706 Kopecka, 2015, Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells, Oncotarget, 6, 6776, 10.18632/oncotarget.2882 Comerford, 2002, Hypoxia-Inducible Factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res, 62, 3387 Riganti, 2005, Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux, Cancer Res, 65, 516, 10.1158/0008-5472.516.65.2 Riganti, 2015, Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein, Cancer Lett., 360, 219, 10.1016/j.canlet.2015.02.008 Callaghan, 2014, Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?, Drug Metab. Dispos., 42, 623, 10.1124/dmd.113.056176 Gazzano, 2018, Folate-targeted liposomal nitrooxy-doxorubicin: an effective tool against P-glycoprotein-positive and folate receptor-positive tumors, J. Control. Release, 270, 37, 10.1016/j.jconrel.2017.11.042 Pluchino, 2012, Collateral sensitivity as a strategy against cancer multidrug resistance, Drug Resist. Updat., 15, 98, 10.1016/j.drup.2012.03.002 Szakács, 2014, Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance, Chem. Rev., 114, 5753, 10.1021/cr4006236 Dong, 2020, Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update, Drug Resist. Updat., 49, 10.1016/j.drup.2020.100681 Loo, 2015, Mapping the binding site of the inhibitor tariquidar that stabilizes the first transmembrane domain of P-glycoprotein, J. Biol. Chem., 290, 29389, 10.1074/jbc.M115.695171 Pajeva, 2009, Structure-activity relationships of tariquidar analogs as multidrug resistance modulators, AAPS J., 11, 435, 10.1208/s12248-009-9118-z Qu, 2002, Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet, Biochemistry, 41, 4744, 10.1021/bi0120897 Raymond, 1989, Mammalian multidrug-resistance gene: correlation of exon organization with structural domains and duplication of an ancestral gene, Proc. Natl. Acad. Sci. U. S. A., 86, 6488, 10.1073/pnas.86.17.6488 Becker, 2009, Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males, Pharmacogenomics, 10, 1743, 10.2217/pgs.09.105 Choi, 2010, Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting, Anaesthesia, 65, 996, 10.1111/j.1365-2044.2010.06476.x Gréen, 2006, Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy, Clin. Cancer Res., 12, 854, 10.1158/1078-0432.CCR-05-0950 Chen, 1986, Internal duplication and homology with bacterial transport proteins in the Mdr1 (P-glycoprotein) gene from multidrug-resistant human cells, Cell, 47, 381, 10.1016/0092-8674(86)90595-7 Omote, 2004, Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation, Biochemistry, 43, 3917, 10.1021/bi035365l Safa, 1990, Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185 → Val-185 substitution in P-glycoprotein, Proc. Natl. Acad. Sci. U. S. A, 87, 7225, 10.1073/pnas.87.18.7225 Harbeck, 2017, Breast cancer, Lancet, 389, 1134, 10.1016/S0140-6736(16)31891-8 Salaroglio, 2018, Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer, J. Exp. Clin. Cancer Res., 37, 286, 10.1186/s13046-018-0967-0